With $85M series B, Athira seeks to recover neuronal health in Alzheimer’s patients

Athira’s crossover-laden $85 million series B round will fund the start of a pivotal trial this year of an Alzheimer’s disease therapy that the company thinks could not only slow disease progression, but also improve cognitive function.

Perceptive Advisors led Athira Pharma Inc.’s round, which included new investors RTW Investments,

Read the full 492 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE